Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial

Bulk rna-seq matrix in this article.Ge T, Zhang H, Zhu X, Teng M, Zhou Y, Wang S, Bian D, Zhang L, Hu H, Guo Q, Su J, Hu S, Yu H, Zhou Y, Huang J, Yang J, Zhu Y, Bao Y, Bao M, Hu X, He W, Zhang P. Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial. EClinicalMedicine. 2025 Dec 10;90:103669. doi: 10.1016/j.eclinm.2025.103669. PMID: 41477564; PMCID: PMC12752746.